MedTrace Logo

Choroidal Thickness and Its Correlations With Ocular Parameters in Primary Open-angle Glaucoma

NCT03966560 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 96

Last updated 2019-05-29

No results posted yet for this study

Summary

Glaucoma is one of the leading causes of blindness worldwide that is a chronic public health problem. Unfortunately, glaucoma can be diagnosed when the disease reaches a certain level in today's conditions. The aim of this study was to investigate the diagnostic methods that can diagnose glaucoma before it reaches the advanced level and to identify pathophysiological processes. In this study, choroidal thickness was investigated in primary open-angle glaucoma cases and its correlations with OCT and multifocal ERG parameters were evaluated.

Conditions

  • Glaucoma, Open-Angle

Interventions

DRUG

Brimonidine Tartrate

Brimonidine tartrate 0.15% 1 eye drop, every day for 6-months

DRUG

Dorzolamide (as Dorzolamide Hydrochloride) 20 Mg/mL and Timolol (as Timolol Maleate) 5 Mg/mL Eye Drops

Dorzolamide and timolol fixed combination 2 eye drops, every day for 6 months

DRUG

Brinzolamide/Timolol 10 MG/1 ML-5 MG/1 ML Ophthalmic Suspension

Brinzolamide and timolol fixed combination 2 eye drops, every day for 6 months

DRUG

Travoprost and Timolol

Travoprost and Timolol fixed combination 1 eye drop, every day for 6 months

DRUG

Bimatoprost and Timolol

Bimatoprost and Timolol fixed combination 1 eye drop, every day for 6 months

DRUG

Latanoprost

Latanoprost 0.005% 1 eye drop, every day for 6 months

Sponsors & Collaborators

  • Afyon Kocatepe University Hospital

    lead OTHER

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
40 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2014-01-31
Primary Completion
2015-01-31
Completion
2015-04-30
FDA Drug
Yes

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03966560 on ClinicalTrials.gov